Inflammatory bowel disease and irritable bowel syndrome: Similarities and differences

Current Opinion in Gastroenterology

Volumn 30, Issue 4, 2014, Pages 352-358

  Barbara, Giovanni ^a   Cremon, Cesare ^a   Stanghellini, Vincenzo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Epithelial barrier; Genes; Inflammatory bowel disease; Irritable bowel syndrome; Microbiota

Indexed keywords

BRAIN; CROHN DISEASE; DIGESTIVE TRACT PARAMETERS; GENE; GENETICS; HEREDITY; HOST; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINAL BARRIER; INTESTINE; IRRITABLE COLON; MEDICAL RESEARCH; MICROFLORA; NONHUMAN; REMISSION; REVIEW; TNFSF15 GENE; ADAPTIVE IMMUNITY; DISEASE PREDISPOSITION; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION; IMMUNOLOGY; INTESTINE MUCOSA; MENTAL STRESS; MICROBIOLOGY; PATHOLOGY; PHENOTYPE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM;

TNFSF15 PROTEIN, HUMAN; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADAPTIVE IMMUNITY; DISEASE SUSCEPTIBILITY; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MICROBIOTA; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STRESS, PSYCHOLOGICAL; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

EID: 84902276814     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000070     Document Type: Review

References (58)

1. Lackner JM, GudleskiGD, Thakur ER, et al. The impact of physical complaints, social environment, and psychological functioning on IBS patients' health perceptions: looking beyond GI symptom severity. Am J Gastroenterol 2014; 109:224-233.
2. McCombie AM, Mulder RT, Gearry RB. How IBD patients cope with IBD: A systematic review. J Crohns Colitis 2013; 7:89-106.
3. Ford AC, Bercik P, Morgan DG, et al. Characteristics of functional bowel disorder patients: A cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther 2014; 39:312-321.
4. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and metaanalysis. Am J Gastroenterol 2012; 107:1474-1482.
5. Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013; 7:322-337.
6. Naliboff BD, Kim SE, Bolus R, et al. Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: A structural equation modeling analysis. Am J Gastroenterol 2012; 107:451-459.
7. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5:1424-1429.
8. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol hepatol 2012; 10:712-721; e714.
9. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013; 58:519-525.
10. Quigley EM, Abdel-Hamid H, BarbaraG, et al. A global perspective on irritable bowel syndrome: A consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012; 46:356-366.
11. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 2009; 136:741-754.
12. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 2013; 144:36-49.
13. Fagundes CP, Glaser R, Hwang BS, et al. Depressive symptoms enhance stress-induced inflammatory responses. Brain Behav Immun 2013; 31:172-176.
14. Mikocka-Walus AA, Gordon AL, Stewart BJ, Andrews JM. A magic pill? A qualitative analysis of patients' views on the role of antidepressant therapy in inflammatory bowel disease (IBD). BMC Gastroenterol 2012; 12:93.
15. Goodhand JR, Greig FI, Koodun Y, et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. Inflamm Bowel Dis 2012; 18:1232-1239.
16. Koloski NA, Jones M, Kalantar J, et al. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: A 12-year prospective populationbased study. Gut 2012; 61:1284-1290.
17. Hong JY, Labus JS, Jiang Z, et al. Regional neuroplastic brain changes in patients with chronic inflammatory and non-inflammatory visceral pain. PLoS One 2014; 9:e84564.
18. Labus JS, Dinov ID, Jiang Z, et al. Irritable bowel syndrome in female patients is associated with alterations in structural brain networks. Pain 2014; 155:137-149.
19. Barbara G, Cremon C, De Giorgio R, et al. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep 2011; 13:308-315.
20. Srinath AI, Walter C, Newara MC, Szigethy EM. Pain management in patients with inflammatory bowel disease: insights for the clinician. Therap Adv Gastroenterol 2012; 5:339-357.
21. Jonefjall B, Strid H, Ohman L, et al. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil 2013; 25:756-e578.
22. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491:119-124.
23. Zucchelli M, Camilleri M, Andreasson AN, et al. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut 2011; 60:1671-1677.
24. Swan C, Duroudier NP, Campbell E, et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFalpha. Gut 2013; 62:985-994.
25. Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for postinfectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138:1502-1513.
26. Major G, Spiller R. Irritable bowel syndrome, inflammatory bowel disease and the microbiome. Curr Opin Endocrinol Diabetes Obes 2014; 21:15-21.
27. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013; 62:1653-1664.
28. Rajilic-Stojanovic M,Shanahan F,Guarner F, de VosWM.Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis 2013; 19:481-488.
29. Hansen R, Russell RK, Reiff C, et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am J Gastroenterol 2012; 107:1913-1922.
30. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut 2013; 62:159-176.
31. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136:1979-1988.
32. Cremon C, Stanghellini V, Pallotti F, et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology 2014. [Epub ahead of print]
33. Porter CK, Tribble DR, Aliaga PA, et al. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008; 135:781-786.
34. Rajilic-Stojanović M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141:1792-1801.
35. Jeffery IB, O'Toole PW,O hman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61:997-1006.
36. Jalanka-Tuovinen J, Salojarvi J, Salonen A, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2013. [Epub ahead of print] 35-fold more uncultured Clostridia. Microbial dysbiosis correlates with the expression of several host gene pathways, including impaired epithelial barrier function.
37. Manichanh C, Eck A, Varela E, et al. Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet. Gut 2014. [Epub ahead of print]
38. Carroll IM, Ringel-Kulka T, Ferrier L, et al. Fecal protease activity is associated with compositional alterations in the intestinal microbiota. PLoS One 2013; 8:e78017.
39. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17:362-381.
40. Piche T. Tight junctions and IBS: The link between epithelial permeability, lowgrade inflammation, and symptom generation? Neurogastroenterol Motil 2014; 26:296-302.
41. Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58:196-201.
42. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367:1626-1635.
43. Martinez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2013; 62:1160-1168.
44. Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011; 17:349-359.
45. Matricon J, Meleine M, Gelot A, et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36:1009-1031.
46. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7:e42777.
47. Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117:636-647.
48. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132:26-37.
49. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126:693-702.
50. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104:392-400.
51. Valdez-Morales EE, Overington J, Guerrero-Alba R, et al. Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrheapredominant irritable bowel syndrome patients: A role for PAR2. Am J Gastroenterol 2013; 108:1634-1643.
52. Balestra B, Vicini R, Cremon C, et al. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. Neurogastroenterol Motil 2012; 24:1118-e1570.
53. Steck N, Mueller K, Schemann M, Haller D. Bacterial proteases in IBD and IBS. Gut 2012; 61:1610-1618.
54. Vanuytsel T, van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2013. [Epub ahead of print]
55. Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: A real association or reflection of occult inflammation? Am J Gastroenterol 2010; 105:1788; 1789-1794; quiz 1795.
56. Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation. Gut 2014; 63:744-752.
57. van Hoboken EA, Thijssen AY, Verhaaren R, et al. Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand J Gastroenterol 2011; 46:981-987.
58. Akbar A, Yiangou Y, Facer P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 2010; 59:767-774.